The Myeloid Therapeutics team is looking forward to participating in the Jefferies London Healthcare Conference beginning November 19, 2024. Members of the management team will meet with investors one-on-one and conduct B-to-B meetings to discuss our industry-leading in vivo mRNA engineering technology. Read more here: https://lnkd.in/gaWX-zQG #Biotech #mRNA #JefferiesHealthcare
关于我们
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer. We invite you to join us on this journey – patients are waiting.
- 网站
-
https://www.myeloidtx.com
Myeloid Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
地点
-
主要
获取路线
300 Technology Sq
2nd Floor
US，Massachusetts，Cambridge，02139
Myeloid Therapeutics员工
动态
-
At #SITC2024 today, we are proud to be making an oral presentation on MT-303, our second?in vivo?mRNA CAR program to reach the clinic. Read more here: https://lnkd.in/gEb_7GdS #Biotech #mRNA
-
-
At #SITC2024 today, we are proud to be making an oral presentation on MT-303, our second?in vivo?mRNA CAR program to reach the clinic. Read more here: https://lnkd.in/gEb_7GdS #Biotech #mRNA
-
-
Look out for the Myeloid team at SITC- the team will be discussing the first invivo mRNA car programs to go into humans.
Are you heading to Houston for SITC? Myeloid Therapeutics will be presenting the pre-clinical development of MT-303, a novel LNP-formulated GPC3-specific CAR mRNA, for in vivo reprogramming of monocytes to treat hepatocellular carcinoma. Meet me at poster 1125 tomorrow during lunch break or from 5-7pm, or head to section 107b at 3:50pm to see our CMO Matthew Maurer presenting pre-clinical and clinical data. https://lnkd.in/eGZr4bn8 #SITC #CARmonocytes #myeloidcells #CARm
-
At 9:30 am today, Myeloid Therapeutics’ CEO, Daniel G., PhD, is speaking at #BioEurope in the Immuno-Oncology session. We look forward to showcasing our science and mRNA-based clinical pipeline. Learn more here: https://lnkd.in/dnuNZ2D #Biotech #mRNA
-
-
#BreakingNews.?Myeloid Therapeutics’?pipeline of?in vivo?therapies continues to advance in the clinic!?We announced today that we are dosing patients with our second?in vivo?mRNA CAR, MT-303, a novel GPC3 targeting RNA CAR, in a Phase 1 study for the treatment of advanced hepatocellular carcinoma, or HCC, the most prevalent form of liver cancer.?Unlike autologous cell therapies, Myeloid's approach focuses on?in vivo?programming of immune cells with off-the-shelf mRNA encoded CAR technology.?? ? Learn more here: https://lnkd.in/g_6xtgdQ ? #invivo #oncology #livercancer #clinicaltrials
-
-
Thank you to the ESMO - European Society for Medical Oncology organizers for showcasing Myeloid Therapeutics' Trials-in-Progress poster on the MYE Symphony Study (NCT05969041), a First-in-Human Phase 1 trial evaluating our innovative MT-302 program.?MT-302 is our lead in vivo mRNA CAR targeting TROP2+ epithelial malignancies. We were pleased to share our progress and hope to see you at this meeting next year! #ESMO2024 #mRNA
-
-
We are excited to continue to tell the Myeloid Therapeutics story at several upcoming conferences in September and October. More details can be found here: https://lnkd.in/grVRs2nV #biotech #mRNA
-
-
The Myeloid Therapeutics team is looking forward to participating in the Barclays Biotech: 1x1 Private Company Symposium on August 7, 2024. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo mRNA engineering technology. Learn more here: https://lnkd.in/gSj6A_xD ? #Biotech #mRNA
-
-
Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year.?It is also the third leading cause of cancer death.?At Myeloid Therapeutics, our mission is to develop RNA therapeutics to conquer cancer - dosing our first patient with MT-303 in our Phase 1 study brings us one step closer to achieving our goal. Thank you to the clinical investigators, study coordinators and participants for helping us advance our research.? ? Learn more about our clinical trials here:?https://lnkd.in/gt-m8NGy ? #invivo #oncology #livercancer #clinicaltrials
-